Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Paclitaxel oral - DAE HWA Pharmaceutical

Next Previous
Drug Profile

Paclitaxel oral - DAE HWA Pharmaceutical

Alternative Names: DHP-107; Liporaxel; RMX-3001

Latest Information Update: 21 Nov 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator DAE HWA Pharmaceutical
  • Developer DAE HWA Pharmaceutical; HaiHe Biopharma
  • Class Albumins; Antineoplastics; Diterpenes; Paclitaxels; Small molecules; Taxanes
  • Mechanism of Action Angiogenesis inhibitors; Mitosis inhibitors; Platelet-derived growth factor inhibitors; Proto-oncogene protein c-bcl-2 inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Gastric cancer
  • Preregistration HER2 negative breast cancer
  • No development reported Solid tumours

Most Recent Events

  • 16 Oct 2025 Registered for Gastric cancer (Second-line therapy or greater, Metastatic disease, Recurrent, Inoperable/Unresectable, Late-stage disease) in China (PO) prior to October 2025
  • 30 Jun 2025 Preregistration for HER2-negative-breast-cancer (Metastatic disease, Recurrent) in China (PO) (HaiHe Biopharma pipeline, August 2026)
  • 30 Jun 2025 NMPA accepts NDA for RMX 3001 for HER2-negative breast cancer (Recurrent, Metastatic disease) for review (HaiHe Biopharma pipeline, August 2026)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top